Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1-Year High – Still a Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares reached a new 52-week high during trading on Friday . The company traded as high as $21.93 and last traded at $21.91, with a volume of 170293 shares traded. The stock had previously closed at $21.41.

Analyst Ratings Changes

A number of analysts have commented on CPRX shares. Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Citigroup lifted their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Price Performance

The business’s 50-day moving average price is $20.37 and its two-hundred day moving average price is $17.61. The company has a market capitalization of $2.53 billion, a P/E ratio of 39.74, a PEG ratio of 3.18 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. The company had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares in the company, valued at $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the last quarter. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $50,000. CWM LLC increased its stake in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at $70,000. Finally, SG Americas Securities LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $173,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.